FDA Issues Corrected Advice To InflaRx's Vilobelimab Study In Skin Disease
InflaRx N.V. (NASDAQ: IFRX) has
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
FORGOTTEN HISTORY: Inflarx n v | History Defined
See Why Did InflaRx Pause Late-Stage Vilobelimab Trial In Chronic Skin Condition
InflaRx N.V. (NASDAQ: IFRX) has received an advice letter from the FDA about the vilobelimab Phase 3 program for hidradenitis suppurativa (HS), a condition that causes small, painful lumps to form under the skin.
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
Organisations
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
